Shattuck Labs officer adds 12,805 shares via warrants
Shattuck Labs, Inc. officer Stephen Stout reported acquiring additional equity through a private placement-related transaction.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Shattuck Labs, Inc. officer Stephen Stout reported acquiring additional equity through a private placement-related transaction. He acquired 12,805 shares of common stock and exercised accompanying warrants for 12,805 shares at an exercise price of $1.0846 per share, bringing his direct holdings to 93,366 common shares. These securities stem from a prior securities purchase agreement where common stock and warrants were originally issued together at a combined price of $0.8677 per share and warrant, with the warrants exercisable during a period tied to clinical data milestones for SL-325.
Insider Trade Summary
12,805 shares exercised/converted
Exercise
2 txns
Insider
Stout Stephen
Role
See Remarks
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Warrants (Right to Buy) | 12,805 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 12,805 | $1.0846 | $14K |
Holdings After Transaction:
Warrants (Right to Buy) — 0 contracts (Direct);
Common Stock — 93,366 shares (Direct)
Footnotes (2)
- F1. On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 12,805 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 12,805 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677.
- F2. The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly.
Key Figures
Common shares acquired: 12,805 shares
Warrants exercised: 12,805 warrants
Warrant exercise price: $1.0846 per share
+3 more
6 metrics
Common shares acquired
12,805 shares
Non-derivative acquisition of common stock
Warrants exercised
12,805 warrants
Derivative exercise into common stock
Warrant exercise price
$1.0846 per share
Conversion or exercise price for underlying common stock
Post-transaction holdings
93,366 shares
Total common shares directly held after transactions
Original combined price
$0.8677 per unit
Per share and accompanying warrant in private placement
Underlying warrant shares
12,805 shares
Common stock underlying exercised warrants
Key Terms
securities purchase agreement, Warrants, Phase 1 clinical trial, multiple ascending dose, +1 more
5 terms
securities purchase agreement financial
"the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors"
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
Warrants financial
"accompanying warrants (the "Warrants") to purchase up to an aggregate of 12,805 shares"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
Phase 1 clinical trial medical
"single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325"
A phase 1 clinical trial is the first stage of testing a new drug or treatment in people, typically involving a small group to assess safety, how the body handles the treatment, and appropriate dosing. For investors, phase 1 results are an early risk check — like a test drive that can reveal fatal flaws or promising signals — and they often cause big changes in a drug’s perceived value and the company’s prospects.
multiple ascending dose medical
"single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial"
A multiple ascending dose is a method used in testing new medicines where small groups of people receive gradually larger amounts of the drug over time. This approach helps researchers find the safest and most effective dose without causing too many side effects. For investors, it signals ongoing steps in drug development that can impact a company's potential success or approval prospects.
Phase 2 clinical trial(s) medical
"and the design of the planned Phase 2 clinical trial(s) have been announced publicly"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Stephen Stout report at Shattuck Labs (STTK)?
Stephen Stout reported acquiring more equity in Shattuck Labs. He obtained 12,805 common shares and exercised warrants for another 12,805 shares, consolidating his position through a private placement-related transaction linked to earlier financing terms.
What was the exercise price of the Shattuck Labs (STTK) warrants in this filing?
The warrants exercised by Stephen Stout carried an exercise price of $1.0846 per share. They related to 12,805 underlying common shares and were originally issued together with common stock in a private placement financing arrangement.
How were the Shattuck Labs (STTK) common stock and warrants originally issued to Stephen Stout?
The common stock and warrants were originally issued under a securities purchase agreement. Stout received 12,805 common shares and accompanying warrants at a combined price of $0.8677 per share and warrant in a private placement that closed on August 25, 2025.
What clinical trial milestone affects the Shattuck Labs (STTK) warrants mentioned here?
The warrants are exercisable from their original issuance date until 30 days after public announcement of Phase 1 SL-325 dose-escalation data and the design of planned Phase 2 trials. That clinical data window defines the outside limit for exercising these warrants.
AI-generated analysis. How Rhea-AI works. Not financial advice.
